December 10, 2019
1 min read

GenSight’s LHON treatment receives French temporary authorization for use

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

A patient at France’s National Eye Hospital of the Quinze-Vingts has been granted temporary authorization for use of Lumevoq, GenSight Biologics’ gene therapy for the treatment of Leber hereditary optic neuropathy, according to a press release.

Lumevoq, also known as GS010, targets LHON by leveraging a mitochondrial targeting sequence proprietary technology platform, which addresses defects in the mitochondria using an adeno-associated virus vector.

The French Competent Authority’s temporary authorization program allows a product not yet approved with a marketing authorization and not recruiting for clinical trials to be used in patients if it is meant to treat, prevent or diagnose a severe or rare disease that has no other treatment.

“France’s ATU program is a powerful means of providing LHON patients with the ND4 mutation with a therapeutic solution, Lumevoq gene therapy,” Catherine Vignal, MD, principal investigator for Lumevoq trials at the department of ophthalmology at Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts and head of the department of neuro-ophthalmology at the Rothschild Foundation, Paris, said in the release. “To me as a clinician, it is important that I can now offer my patients a treatment for their condition, in close collaboration with the Regulatory Competent Authorities, while waiting for official marketing authorization.”